Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 10/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 2/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 8/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733914 | 0.89 | CYP2C19 (0.57) | BLMCYP2C19SMN1; SMN2LDHAPOLB | |
| SCHEMBL15601884 | 0.87 | LDHA (0.47) | BLMSRCCYP2C19SMN1; SMN2GRB2 | |
| SCHEMBL14369505 | 0.86 | BLM (0.45) | BLMSRCCYP2C19SMN1; SMN2GRB2 | |
| SCHEMBL20714775 | 0.83 | BLM (0.51) | BLMSRCCYP2C19SMN1; SMN2CA1 | |
| SCHEMBL9293068 | 0.80 | ESR1 (0.48) | BLM | |
| SCHEMBL14490963 | 0.80 | SRC (0.47) | BLMSRCGRB2ZAP70 | |
| SCHEMBL15315066 | 0.80 | SRC (0.47) | BLMSRCGRB2ZAP70 | |
| SCHEMBL3123300 | 0.80 | SLC6A4 (0.58) | BLM | |
| SCHEMBL21807707 | 0.80 | SLC6A4 (0.58) | BLM | |
| SCHEMBL28439356 | 0.80 | SRC (0.40) | BLMSRCCYP2C19SMN1; SMN2GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053310-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053310-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, IAPP, GCG | BLM 4023/4885SRC 4778/4885CYP2C19 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.